Related Experiment Video
Updated: Jan 12, 2026
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Targeting ROS1 in NSCLC: Clinical Advances and Future Directions of Taletrectinib
Manoj Kumbhare1, Nishant Dattatray Pagere1, Bhagwan Ide1
1Department of Pharmaceutical Chemistry, SMBT College of Pharmacy, Dhamangaon, Nashik - 422403, India.
Abstract:
This review looks at the pharmacokinetics, safety, and effectiveness of taletrectinib, a novel inhibitor that targets both ROS1 and NTRK, in patients with solid tumors and ROS1-positive non-small cell lung cancer (NSCLC). Objective response rates (ORR), progression-free survival (PFS), intracranial efficacy, and safety profiles are evaluated in the Review using phase I and phase II clinical trials, including both domestic and foreign research projects. Findings show that taletrectinib has a promising anticancer impact, good CNS penetration, and a solid safety record, especially in patients with brain metastases. These results imply that ROS1-positive cancers may benefit from taletrectinib as a treatment.
Insights
Taletrectinib shows promise for treating ROS1-positive cancers, including non-small cell lung cancer (NSCLC). This novel inhibitor demonstrates anticancer effects, good central nervous system (CNS) penetration, and a favorable safety profile, particularly for brain metastases.
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- Taletrectinib is a novel inhibitor targeting ROS1 and NTRK.
- ROS1-positive cancers, including non-small cell lung cancer (NSCLC), represent a significant therapeutic challenge.
Purpose of the Study:
- To review the pharmacokinetics, safety, and effectiveness of taletrectinib.
- To evaluate taletrectinib's efficacy in patients with solid tumors and ROS1-positive NSCLC.
Main Methods:
- Review of Phase I and Phase II clinical trials.
- Evaluation of objective response rates (ORR), progression-free survival (PFS), and intracranial efficacy.
- Assessment of safety profiles in domestic and international research.
Main Results:
- Taletrectinib exhibits promising anticancer activity.
- The drug demonstrates good central nervous system (CNS) penetration.
- A solid safety record was observed, especially in patients with brain metastases.
Conclusions:
- Taletrectinib is a potential treatment option for ROS1-positive cancers.
- Its efficacy in treating brain metastases is noteworthy.
- Further research supports taletrectinib's role in oncology.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
10:35A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
Published on: April 5, 2018
